All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

EHA 2019 | How will the sequencing of treatments for DLBCL change in the future?

Jun 20, 2019

Bookmark this article

At the 24th Congress of the European Hematology Association (EHA), Ulrich Jäger from the Medical University of Vienna, Vienna, AT, discusses how to decide what treatments to use, and when, for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Professor Jäger notes that we now have many options for treating patients with lymphomas, such as DLBCL and the question is how to determine the appropriate treatment for each patient when they relapse or become refractory to treatment. A few options were described, such as CAR T, bi-specific antibodies, conjugated antibodies and chemotherapeutic agents.

Professor Jäger raised several questions; how to bridge patients to receive CAR T? Will patients who receive bispecific antibodies need CAR T?

Additionally, it was noted that there is a data issue in this treatment dilemma. After CAR T relapse, some patients survive a long time indicating some treatments rescue patients after CAR T, however currently we do not know what these therapies are, so there is work to do here.

How will the sequencing of treatments for DLBCL change in the future?

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you


Subscribe to get the best content related to lymphoma & CLL delivered to your inbox